Pfizer's Plan Comes Together
Updated from 1:25 p.m. EDT
Pfizer's (PFE) second-quarter financial results beat Wall Street's estimates, and the company provided no financial shocks, but executives also indicated that job cuts would be coming soon as part of a previously announced restructuring.
Henry McKinnell, the chairman and CEO, told analysts during a telephone conference that Pfizer was able to show a gain in revenue despite generic competition for several drugs, the withdrawing of the arthritis drug Bextra and the "rebuilding" of sales for the arthritis drug Celebrex.
He reiterated that he expects Pfizer to post double-digit earnings-per-share growth in 2006 and even greater double-digit profit growth in 2007."I love it when a plan comes together," said McKinnell, citing the signature comment from Col. Hannibal Smith in the
Reducing ExpensesThe company did alter its forecast, revising its full-year revenue prediction to "a modest decline" vs. 2004 rather than the previous estimate that revenue would be unchanged.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV